Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea

Blood (2020) 136 (Supplement 1): 9.

https://doi.org/10.1182/blood-2020-136120

Published: 2020

Journal Articles

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

Blood (2019) 134 (Supplement_1): 185.

https://doi.org/10.1182/blood-2019-131390

Published: 2019

Journal Articles

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Diana Abbott, PhD, Andrew Hammes, MS, Jonathan A Gutman, MD, Daniel A Pollyea, MD, Clayton Smith, MD

Blood (2019) 134 (Supplement_1): 5897.

https://doi.org/10.1182/blood-2019-126344

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Blood (2019) 134 (Supplement_1): 2638.

https://doi.org/10.1182/blood-2019-122120

Published: 2019

Journal Articles

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Jonathan A Gutman, MD, Prashant Sharma, MD, Enkhtsetseg Purev, MD, Clayton Smith, MD, Amanda Winters, MD PhD, Andrew Hammes, MS, Michael R. Loken, PhD, Daniel A Pollyea, MD

Blood (2019) 134 (Supplement_1): 4615.

https://doi.org/10.1182/blood-2019-129150

Published: 2019

Journal Articles

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Daniel A Pollyea, MD, Courtney L Jones, PhD, Brett M Stevens, PhD, Shanshan Pei, PhD, Angelo D'Alessandro, PhD, Rachel Culp-Hill, BS, Diana Abbott, PhD, Andrew Hammes, MS, James Dugan, MD, Jonathan A Gutman, MD, Enkhtsetseg Purev, MD PhD, Clayton Smith, MD, Craig T Jordan, PhD

Blood (2018) 132 (Supplement 1): 432.

https://doi.org/10.1182/blood-2018-99-111507

Published: 2018

Journal Articles

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Brett M. Stevens, PhD, Amanda Winters, MD PhD, Jonathan A Gutman, MD, Aaron Fullerton, BS, Gregory Hemenway, MS2, Nicholas Miltgen, BS, Qi Wei, MD, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Neeraj Kumar Singh, B.Tech, Leylah M. Drusbosky, PhD, Chris R. Cogle, MD, Andrew Hammes, MS, Craig T. Jordan, PhD, Daniel A. Pollyea, MD

Blood (2017) 130 (Supplement 1): 1337.

https://doi.org/10.1182/blood.V130.Suppl_1.1337.1337

Published: 2017

Journal Articles

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Peter A. Forsberg, MD, Tomer M Mark, MDMSc, Daniel W. Sherbenou, MDPhD, Andrew Hammes, MS, Adriana C. Rossi, MDMSc, Ruben Niesvizky, MD, David S Jayabalan, MSc, Scott Ely, MDMPH

Blood (2017) 130 (Supplement 1): 3059.

https://doi.org/10.1182/blood.V130.Suppl_1.3059.3059

Published: 2017

NARROW

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy

How Median Follow-up Time Informs Survival Outcomes: Lessons from a Trial of Acute Myeloid Patients Treated with Venetoclax and Azacitidine

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide Therapy

Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Receiving Induction Only and Are Superior to MRD Positive Patients Receiving Induction and Additional Therapy

Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1

Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics

Cellular Proliferation By Multiplex Immunohistochemistry Identifies Aggressive Disease Behavior in Relapsed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only